Lempo Therapeutics is a pre-clinical biotech company, pioneering a paradigm shift in the modification of the innate immune system to effectively combat autoimmune and life threatening progressive diseases. Our patented novel treatment uses ex-vivo stem cells gene-editing technique to minimize the collateral damage caused by the immune system as a result of its activity. By doing so, we expect to significantly attenuate the progression of diseases. This approach has already been proven to work in animal models of Alzheimer's Disease, Multiple Sclerosis, cardiovascular diseases, and more. We focus first on treating Pulmonary Arterial Hypertension (PAH) and ANCA-associated Vasculitis(AAV), both rare, devastating diseases with no available cure and poor prognosis.